Dew, it would be appreciated if you substantiated your opinion with facts rather than coming up with what's on your mind only to create an impression. Feel free to post on the YMB if you cant substantiate them. There is no reason for big pharma to neglect a new mechanism of action that can be coupled with NNRTIs, whether the first indication targets a portion of the markets does not preclude expanding the indication with the same or future drugs derived from it.